糖尿病性心肌病的超声心动图特征：我们目前处于什么阶段？
Echocardiographic feature of diabetic cardiomyopathy: where are we now?
作者信息
Negishi Kazuaki
机构信息
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Royal Hobart Hospital, Hobart, Australia.
出版信息
Cardiovasc Diagn Ther. 2018 Feb;8(1):47-56. doi: 10.21037/cdt.2018.01.03.
Abstract
We are now entering the very exciting era of treatment and management of diabetes mellitus (DM) with the emergence of new therapeutic agents, including sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP-4i). From a cardiology and echocardiography perspective, the existence of diabetic cardiomyopathy has been proven through over four decades of discussion. DM is highly prevalent in patients with heart failure (HF). Independent associations are found after adjusting for hypertension (HTN) and coronary artery disease (CAD). In patients with both DM and HF, the prognosis is extremely dismal. In this review, the main focus is on both diabetic cardiomyopathy and its typical features (including myocardial additive insult related to DM), diagnosis, and management.
摘要
随着新型治疗药物的出现，包括钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）和二肽基肽酶-4抑制剂（DPP-4i），我们现在正进入糖尿病（DM）治疗和管理的非常激动人心的时代。从心脏病学和超声心动图的角度来看，经过四十多年的讨论，糖尿病性心肌病的存在已得到证实。DM在心力衰竭（HF）患者中非常普遍。在调整高血压（HTN）和冠状动脉疾病（CAD）后发现存在独立关联。在患有DM和HF的患者中，预后极其糟糕。在本综述中，主要关注糖尿病性心肌病及其典型特征（包括与DM相关的心肌附加损伤）、诊断和管理。
相似文献
1
Echocardiographic feature of diabetic cardiomyopathy: where are we now?
Cardiovasc Diagn Ther. 2018 Feb;8(1):47-56. doi: 10.21037/cdt.2018.01.03.
2
Diabetes Mellitus and Heart Failure.
J Clin Med. 2021 Aug 19;10(16):3682. doi: 10.3390/jcm10163682.
3
Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure - Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
Circ J. 2017 Oct 25;81(11):1662-1669. doi: 10.1253/circj.CJ-17-0240. Epub 2017 Jun 6.
4
Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice.
Int J Endocrinol. 2017;2017:1365209. doi: 10.1155/2017/1365209. Epub 2017 Mar 19.
5
Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Circ Heart Fail. 2017 Sep;10(9). doi: 10.1161/CIRCHEARTFAILURE.117.003957.
6
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
Int J Cardiol. 2015 Feb 15;181:239-44. doi: 10.1016/j.ijcard.2014.12.017. Epub 2014 Dec 3.
7
Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Int J Cardiol. 2016 Oct 1;220:595-601. doi: 10.1016/j.ijcard.2016.06.208. Epub 2016 Jun 27.
8
Diabetic Cardiomyopathy: Clinical and Metabolic Approach.
Curr Vasc Pharmacol. 2021;19(5):487-498. doi: 10.2174/1570161119999201102213214.
9
Isolated type 2 diabetes mellitus causes myocardial dysfunction that becomes worse in the presence of cardiovascular diseases: results of the myocardial doppler in diabetes (MYDID) study 1.
Cardiology. 2005;103(4):189-95. doi: 10.1159/000085126. Epub 2005 Apr 12.
10
Impaired myocardial functional reserve in hypertension and diabetes mellitus without coronary artery disease: Searching for the possible link with congestive heart failure in the myocardial Doppler in diabetes (MYDID) study II.
Am J Hypertens. 2006 Aug;19(8):851-7; discussion 858. doi: 10.1016/j.amjhyper.2006.01.005.
引用本文的文献
1
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives.
Pharmaceuticals (Basel). 2025 Jan 20;18(1):134. doi: 10.3390/ph18010134.
2
Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes.
Int J Mol Sci. 2024 Oct 2;25(19):10617. doi: 10.3390/ijms251910617.
3
Diabetic cardiomyopathy: an educational review.
Br J Cardiol. 2023 Jun 13;30(2):18. doi: 10.5837/bjc.2023.018. eCollection 2023.
4
Early Identification and Management of Heart Failure in Patients with Diabetes Mellitus in the United Arab Emirates: A Call to Action.
J Saudi Heart Assoc. 2023 Aug 5;35(2):192-199. doi: 10.37616/2212-5043.1342. eCollection 2023.
5
Echocardiographic Changes in Saudi Patients with Type 2 Diabetes Mellitus.
Medicina (Kaunas). 2023 Nov 10;59(11):1985. doi: 10.3390/medicina59111985.
6
Abnormal left ventricular systolic reserve function detected by treadmill exercise stress echocardiography in asymptomatic type 2 diabetes.
Front Cardiovasc Med. 2023 Oct 19;10:1253440. doi: 10.3389/fcvm.2023.1253440. eCollection 2023.
7
Multi-modality cardiac imaging in the management of diabetic heart disease.
Front Cardiovasc Med. 2022 Nov 3;9:1043711. doi: 10.3389/fcvm.2022.1043711. eCollection 2022.
8
Cardiac Morphology, Function, and Hemodynamics in Patients With Morbid Obesity and Nonalcoholic Steatohepatitis.
J Am Heart Assoc. 2021 Apr 20;10(8):e017371. doi: 10.1161/JAHA.120.017371. Epub 2021 Apr 13.
9
Echocardiography, an Indispensable Tool for the Management of Diabetics, with or without Coronary Artery Disease, in Clinical Practice.
Medicina (Kaunas). 2020 Dec 18;56(12):709. doi: 10.3390/medicina56120709.
10
Mitochondrial Dysfunction in Diabetic Cardiomyopathy: The Possible Therapeutic Roles of Phenolic Acids.
Int J Mol Sci. 2020 Aug 22;21(17):6043. doi: 10.3390/ijms21176043.
本文引用的文献
1
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
2
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6. Epub 2017 Mar 18.
3
Dual-Imaging Stress Echocardiography for Prognostic Assessment of High-Risk Asymptomatic Patients with Diabetes Mellitus.
J Am Soc Echocardiogr. 2017 Feb;30(2):149-158. doi: 10.1016/j.echo.2016.10.003. Epub 2016 Nov 11.
4
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
5
Mitral Regurgitation and Increased Risk of All-Cause and Cardiovascular Mortality in Patients with Type 2 Diabetes.
Am J Med. 2017 Jan;130(1):70-76.e1. doi: 10.1016/j.amjmed.2016.07.016. Epub 2016 Aug 20.
6
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
7
Pathophysiological effects of different risk factors for heart failure.
Open Heart. 2016 Mar 18;3(1):e000339. doi: 10.1136/openhrt-2015-000339. eCollection 2016.
8
Impact of Improved Glycemic Control on Cardiac Function in Type 2 Diabetes Mellitus.
Circ Cardiovasc Imaging. 2016 Mar;9(3):e003643. doi: 10.1161/CIRCIMAGING.115.003643.
9
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
N Engl J Med. 2016 Apr 7;374(14):1321-31. doi: 10.1056/NEJMoa1506930. Epub 2016 Feb 17.
10
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.
Nat Rev Endocrinol. 2016 Mar;12(3):144-53. doi: 10.1038/nrendo.2015.216. Epub 2015 Dec 18.
Zotero 插件